Johnson Fistel, PLLP is investigating potential securities law violations on behalf of Beta Bionics investors. The investigation concerns whether Beta Bionics or certain executive officers made false or misleading statements or failed to disclose material information about the company's growth trends, new patient starts, business outlook, and related operating metrics. On January 8, 2026, Beta Bionics announced preliminary unaudited fourth-quarter 2025 results, expecting at least 5,581 new patient starts, representing year-over-year growth of at least 36%. Despite the growth, the results fell below analyst expectations and reflected a significant deceleration from the prior quarter's 68% year-over-year growth in new patient starts. Investors who purchased Beta Bionics securities and suffered losses are encouraged to contact Johnson Fistel to discuss their legal rights.
Beta Bionics, Inc. Common StockInvestigation for potential securities law violations regarding misleading statements about growth trends and new patient starts.